ClinicalTrials.gov
ClinicalTrials.gov Menu

Study To Evaluate Long Term Treatment Effect Of Diapep277® In Patients Who Have Completed Study 901 And Study 910** (Extension To 901)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01281072
Recruitment Status : Unknown
Verified January 2011 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : January 21, 2011
Last Update Posted : January 21, 2011
Sponsor:
Collaborator:
DIABETES UNIT
Information provided by:
Hadassah Medical Organization

Brief Summary:
Open label study to evaluate long term treatment effect of diapep277.

Condition or disease Intervention/treatment Phase
Giving a Vaccination in Three Months Other: vaccine Phase 3

Study Type : Interventional  (Clinical Trial)
Intervention Model: Single Group Assignment



Primary Outcome Measures :
  1. c peptide reserve


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

1. patient that completed 901 and 910 study.

Exclusion Criteria:

1. cpeptide<0.2


Responsible Party: PROP ITAMAR RAZ, HADASSAH MEDICAL CENTER
ClinicalTrials.gov Identifier: NCT01281072     History of Changes
Other Study ID Numbers: 911-DIAPEP277
First Posted: January 21, 2011    Key Record Dates
Last Update Posted: January 21, 2011
Last Verified: January 2011